Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

Candel Therapeutics, Inc. CADL announced that the FDA has granted orphan drug designation to its lead investigational adenovirus immunotherapy candidate, CAN-2409, for the treatment of pancreatic ...

NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Shares of Candel Therapeutics Inc. CADL, -5.31% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment. Pancreatic cancer patients who ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Sonrai Analytics has entered a strategic partnership with Candel Therapeutics to expedite the development of viral ...

Friday, Candel Therapeutics Inc CADL shares are trading higher on heavy volume with a session volume of 7.89 million versus the average volume of 2.37 million, as per data from Benzinga Pro.

Results come after Candel downsized to focus on core assets Shares of Candel Therapeutics Inc. (CADL) climbed 15% early Friday after the company released new data from a trial of its experimental ...